| RNA Interference and Gene Delivery | Lifetime | 20 | CN 4 | 99.88 |
| MicroRNA in disease regulation | Lifetime | 31 | CN 7 | 99.78 |
| Nanoparticle-Based Drug Delivery | Lifetime | 18 | CN 6 | 99.87 |
| Nanoplatforms for cancer theranostics | Lifetime | 35 | CN 23 | 99.82 |
| Advanced biosensing and bioanalysis techniques | Lifetime | 172 | CN 75 | 99.51 |
| Circular RNAs in diseases | Lifetime | 66 | CN 34 | 99.30 |
| Cancer-related molecular mechanisms research | Lifetime | 185 | CN 78 | 99.23 |
| Immune cells in cancer | Lifetime | 106 | CN 6 | 99.27 |
| Extracellular vesicles in disease | Lifetime | 126 | CN 28 | 98.59 |
| biodegradable polymer synthesis and properties | Lifetime | 196 | CN 38 | 99.09 |
| Graphene and Nanomaterials Applications | Lifetime | 134 | CN 60 | 99.04 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 476 | CN 24 | 98.92 |
| Immunotherapy and Immune Responses | Lifetime | 780 | CN 17 | 98.79 |
| Virus-based gene therapy research | Lifetime | 624 | CN 15 | 98.23 |
| Congenital heart defects research | Lifetime | 221 | CN 5 | 98.14 |
| Dendrimers and Hyperbranched Polymers | Lifetime | 121 | CN 26 | 97.82 |
| Cancer Research and Treatments | Lifetime | 501 | CN 27 | 97.41 |
| CAR-T cell therapy research | Lifetime | 738 | CN 16 | 98.05 |
| Reproductive System and Pregnancy | Lifetime | 544 | CN 24 | 97.30 |
| Neuroinflammation and Neurodegeneration Mechanisms | Lifetime | 722 | CN 45 | 97.75 |
| Advanced Polymer Synthesis and Characterization | Lifetime | 427 | CN 71 | 97.82 |
| Inflammasome and immune disorders | Lifetime | 373 | CN 30 | 96.47 |
| Phagocytosis and Immune Regulation | Lifetime | 218 | CN 12 | 96.20 |
| Polymer Surface Interaction Studies | Lifetime | 471 | CN 94 | 97.10 |
| Advanced Drug Delivery Systems | Lifetime | 474 | CN 51 | 96.52 |
| Hydrogels: synthesis, properties, applications | Lifetime | 520 | CN 136 | 95.69 |
| Barrier Structure and Function Studies | Lifetime | 711 | CN 29 | 88.30 |
| Lymphatic Disorders and Treatments | Lifetime | 629 | CN 29 | 62.88 |
| Immune cells in cancer | 2021-2025 | 12 | CN 8 | 99.48 |
| Immunotherapy and Immune Responses | 2021-2025 | 41 | CN 10 | 99.30 |
| Extracellular vesicles in disease | 2021-2025 | 34 | CN 24 | 98.88 |
| Nanoplatforms for cancer theranostics | 2021-2025 | 85 | CN 71 | 99.37 |
| Immune Cell Function and Interaction | 2021-2025 | 127 | CN 30 | 98.13 |
| Nanoparticle-Based Drug Delivery | 2021-2025 | 58 | CN 21 | 98.52 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 219 | CN 34 | 99.15 |
| RNA Interference and Gene Delivery | 2021-2025 | 83 | CN 42 | 98.28 |
| Phagocytosis and Immune Regulation | 2021-2025 | 25 | CN 9 | 94.86 |
| MicroRNA in disease regulation | 2021-2025 | 248 | CN 154 | 96.88 |
| CAR-T cell therapy research | 2021-2025 | 432 | CN 36 | 97.28 |
| Lung Cancer Research Studies | 2021-2025 | 209 | CN 38 | 97.35 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 271 | CN 26 | 95.31 |
| Reproductive System and Pregnancy | 2021-2025 | 154 | CN 58 | 95.16 |
| Neuroinflammation and Neurodegeneration Mechanisms | 2021-2025 | 374 | CN 120 | 93.94 |
| Inflammasome and immune disorders | 2021-2025 | 206 | CN 105 | 92.75 |
| Cancer Cells and Metastasis | 2021-2025 | 424 | CN 86 | 89.82 |
| Cancer, Stress, Anesthesia, and Immune Response | 2021-2025 | 72 | CN 24 | 88.93 |
| Luminescence and Fluorescent Materials | 2021-2025 | 877 | CN 727 | 92.94 |
| Circular RNAs in diseases | 2021-2025 | 619 | CN 442 | 89.11 |
| Graphene and Nanomaterials Applications | 2021-2025 | 995 | CN 261 | 85.67 |
| Cancer Research and Treatments | 2021-2025 | 637 | CN 266 | 82.26 |
| Heme Oxygenase-1 and Carbon Monoxide | 2021-2025 | 393 | CN 171 | 74.34 |
| Congenital heart defects research | 2021-2025 | 881 | CN 139 | 71.75 |
| Barrier Structure and Function Studies | 2021-2025 | 484 | CN 110 | 60.30 |
| Healthcare and Venom Research | 2021-2025 | 906 | CN 305 | 50.38 |
